Navigation Links
Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results

LAVAL, QC, Sept. 28 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB), is pleased to report its financial results for the fiscal year ended May 31, 2007. During the last fiscal year, Neptune improved its productivity and operational profitability while continuing its business development strategy to penetrate the American, European and Asian markets, resulting in sustainable sales growth.

Financial Results and Highlights:

- Sales increased by 18% to $8,126,000 from $6,912,000 in the preceding

fiscal year.

- EBITDA increased by 43% to $1,504,000 from $1,049,000 in the preceding

fiscal year, representing a third consecutive year with a positive


- EBITDA margin reached 18.5%, compared to 15.2% in the preceding fiscal


- Excluding stock-based compensation expenses, Neptune would have

realized earnings of $152,000 instead of a loss of $2,677,000 in the

fiscal year ended May 31, 2007. Excluding stock-based compensation

expenses and an extraordinary gain from the settlement of debentures,

Neptune would have realized a loss of $1,574,000 instead of a loss of

$886,000 in the fiscal year ended May 31, 2006.

"We believe that the evaluation model and accounting method for stock-based compensation expenses are not appropriate for small capitalization fast growing companies. They do not bring the accounting value of stock-based compensation closer to the market value, as they should and as they were implemented for", stated Xavier Harland, Director of Finance.

"Neptune has managed to increase its EBITDA by $455,000 with a $1.2M increase in sales, confirming its improvement in operational efficiency", stated Andre Godin, Vice-President, Administration and Finance.

Neptune continues to strongly support its strategic development plan to pursue partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. In accordance with its plan, Neptune has signed agreements with Nestle and Yoplait, paving the way for its entrance into the global functional food market. Neptune is in negotiations with pharmaceutical companies with the short-term objective of penetrating the pharmaceutical market.

About Neptune Technologies & Bioressources Inc.

Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

TSX venture exchange does not accept responsibility for the adequacy or

accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
Breaking Biology News(10 mins):